Alkermes reiterates $400M-$420M Q4 proprietary net sales outlook and targets mid-2027 for alixorexton Phase III data

Summary

Alkermes reiterated its outlook for fourth-quarter proprietary net sales of $400 million to $420 million and is targeting mid-2027 for Phase III data for its alixorexton drug candidate, according to a Seeking Alpha breaking news item. The report is based only on the headline, as no article text was available, so no quarterly results, trial design or company commentary are included.

Timeline

1. Seeking Alpha

   4 Nov 2026, 00:17 UTCSource ↗

   Reports that Alkermes reiterated its $400M-$420M Q4 proprietary net sales outlook while targeting mid-2027 for alixorexton Phase III data.